GKV Capital Management Co. Inc. Makes New Investment in Edwards Lifesciences Co. (NYSE:EW)

GKV Capital Management Co. Inc. bought a new stake in shares of Edwards Lifesciences Co. (NYSE:EW) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 12,295 shares of the medical research company’s stock, valued at approximately $910,000.

A number of other hedge funds have also recently made changes to their positions in EW. Crowley Wealth Management Inc. bought a new stake in Edwards Lifesciences in the fourth quarter worth $26,000. Millstone Evans Group LLC bought a new position in Edwards Lifesciences in the 4th quarter worth about $29,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Edwards Lifesciences during the 4th quarter valued at about $30,000. Roble Belko & Company Inc bought a new stake in Edwards Lifesciences during the 4th quarter valued at about $46,000. Finally, Catalyst Capital Advisors LLC purchased a new position in Edwards Lifesciences in the fourth quarter worth about $54,000. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Stock Performance

EW opened at $71.29 on Thursday. The company has a 50 day simple moving average of $71.29 and a two-hundred day simple moving average of $70.76. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The firm has a market cap of $41.91 billion, a P/E ratio of 10.23, a PEG ratio of 4.82 and a beta of 1.15. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $95.25.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Equities analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on EW. Royal Bank of Canada reissued an “outperform” rating and set a $85.00 price target on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Morgan Stanley boosted their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 12th. Piper Sandler increased their price objective on Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research report on Wednesday, February 12th. Barclays boosted their target price on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 13th. Finally, Evercore ISI dropped their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a report on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $78.55.

Insider Buying and Selling

In related news, VP Donald E. Bobo, Jr. sold 9,500 shares of the company’s stock in a transaction on Monday, April 14th. The shares were sold at an average price of $69.81, for a total transaction of $663,195.00. Following the completion of the transaction, the vice president now owns 47,206 shares in the company, valued at approximately $3,295,450.86. This represents a 16.75 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Bernard J. Zovighian sold 6,164 shares of Edwards Lifesciences stock in a transaction on Monday, March 10th. The shares were sold at an average price of $69.51, for a total transaction of $428,459.64. Following the completion of the sale, the chief executive officer now owns 59,083 shares in the company, valued at approximately $4,106,859.33. This represents a 9.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 71,853 shares of company stock worth $5,163,062. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.